{"prompt": "['ViiV', 'Healthcare', 'From:', 'PPD', 'Sent: Monday, May 04, 2020 1:31 PM', 'To: Sherene Min PPD', 'Subject: Prot-Amend4-208090-sponsign', 'Dear Sponsor,', 'To approve the clinical protocol indicated below, reply to this email and state your approval.', 'PROTOCOL NUMBER: 208090', 'DOCUMENT IDENTIFIER: 2017N331008 06', 'AMENDMENT NUMBER: 04PROTOCOL TITLE: A Phase III, randomized, multicenter, open-label, non-', 'inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed', 'dose combination in HIV-1 infected adults who are virologically suppressed', 'Name of Sponsor Signatory:', 'Sherene Shakib Min, MD, MPH', 'Title of Sponsor Signatory:', 'Vice President and Head of Clinical Development, ViiV Healthcare', '2']['2017N331008_0', 'CONFIDENTIAL', '208090', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', 'DOCUMENT HISTORY', 'Document', 'Date', 'DNG Number', 'Protocol Amendment 04', '05-MAY-2020', '2017N331008_06', 'Protocol Amendment 03/SWE-', '29-JUL-2019', '2017N331008_05', 'DEN-1', 'Protocol Amendment 03/CHI-1', '81-MAY-2019', '2017N331008_04', 'Protocol Amendment 03', '25-MAR-2019', '2017N331008_03', 'Protocol Amendment 02', '14-NOV-2018', '2017N331008_02', 'Protocol Amendment 01', '26-MAR-2018', '2017N331008_01', 'Original', '25-JAN-2018', '2017N331008_00', 'Amendment 04, 05-MAY-2020', 'Overall Rationale for the Amendment: A global amendment, applicable to all', 'participating countries (updates from global protocol amendment 04 will be incorporated', 'into a country specific amendment for China, called 208090 Amendment 04/CHI-1). This', 'amendment describes possible changes in patient management related to the impact of', 'COVID-19, COVID-19 case definition guidance, ending recruitment due to COVID-19', 'before the original sample size was achieved and sample size considerations and', 'statistical analyses updates. Additionally, the list of prohibited medications was updated', 'to add fampridine to align with the Investigator Brochure version 13 and other', 'administrative updates were made to provide updated information, correct errors and', 'improve accuracy and consistency.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Title Page', 'Updated authors', 'To reflect authors', 'of current', 'amendment', 'Sponsor Signatory', 'Updated Sponsor signatory', 'To align with ViiV', 'name and title', 'organizational', 'updates', 'Section1.1, Synopsis', 'Added text to clarify that the', 'To add clarity in', 'study will limit the enrolment', 'of participants with current', 'the Synopsis in', 'order to align with', 'or prior exposure to DTG to', 'protocol section', 'approximately 20%.', '4.2', 'Added text that continuation', 'Section 1.1, Synopsis', 'To clarify country', 'phase is not applicable for', 'Section 1.2, Schema', 'Sweden and Denmark', 'specific', 'requirements for', 'Section 1.3, Schedule of Activities', 'Sweden and', 'Denmark in the', 'Section 4.1, Overall Design', 'body of the', '4']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 4.3, Participant and Study Completion', 'protocol to align', 'Section 6.8, Treatment after the end of the Study', 'with Appendix 13', 'Section 1.1, Synopsis', 'Updated statistical', 'The COVID-19', 'hypotheses and sample size', 'Section 4.1, Overall Design', 'determination.', 'pandemic of', '2019/2020', 'Section 4.2, Number of Participants', 'occurred during', 'Section 4.4, Scientific Rationale for Study Design', 'screening', 'resulting in', 'Section 9, Statistical Considerations', 'planned', 'enrolment being', 'terminated when', 'approximately', '445 participants', 'were randomized', 'and 53 were in', 'screening', 'Section 1.3, Schedule of Activities', 'Updated table and footnote', 'To clarify when', 'Section 8, Study Assessments and Procedures', 'menopause', 'history data will', 'be collected', 'Added creatine', 'Section 1.3, Schedule of Activities', 'To allow for', 'phosphokinase to the list of', 'collection of this', 'Section 11.7, Appendix 7: Clinical Laboratory Tests', 'labs collected as part of', 'lab in addition to', 'clinical chemistry in', 'the other liver', 'Appendix 7, footnote', 'included in Schedule of', 'chemistry tests', 'Activities to refer to', 'already collected', 'Appendix 7 and other', 'footnote letters adjusted', 'accordingly', 'Section 2, Introduction', 'Summary of TANGO Week', '48 data added', 'To provide data', 'that has become', 'available since', 'the prior', 'amendment', 'version', 'Added text to describe', 'Section 2.3.1, Risk Assessment', 'To provide new', 'fampridine risk and updated', 'information from', 'results from the Botswana', 'the updated', 'birth outcome surveillance', 'Investigator', 'study for DTG and neural', 'Brochure version', 'tube defects', '13', 'Added text', 'Section 4.3, Participant and Study Completion', 'To aid clarity', 'Added reference to COVID-', 'Section 6.5,', 'To link appendix', '19 appendix 14', '14 to the main', '5']\n\n###\n\n", "completion": "END"}